Press Releases

Welcome to the Investing News Network's press release section, where you can stay informed with past and present announcements from our clients. Explore the latest stock news from mining, technology and life science companies and gain an investing edge by staying up to date with today's press releases.
Filters
Clear All Filters
Filter ✕

Date Range

Sector

Successful Completion of Placement to Accelerate Clinical Programs

life science investing
Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Sirona Biochem (SBM:CA)

Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare's Landmark Report

Cardiol Therapeutics (CRDL:CA)

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis

Sirona Biochem (SBM:CA)

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

life science investing
Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics to Advance CardiolRx into a Late-Stage Trial in Patients with Recurrent Pericarditis

InhaleRx Secures $38,500,000 Funding to Fully Fund Clinical Development Plans

life science investing
Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Sirona Biochem (SBM:CA)

SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Product Rollout

Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

pharmaceutical investing

FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

pharmaceutical investing
Cardiol Therapeutics (CRDL:CA)

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Latest News

More News
×